Phase 2 Readout~quarter

Phase 2 Readout: aleniglipron

Indication
obesity or overweight and type 2 diabetes mellitus

Other upcoming events for GPCR

Patent ExpiryPatent/Exclusivity Expiry: LEGUBETI
Phase 3 ReadoutPhase 3 Topline: IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Patent ExpiryPatent/Exclusivity Expiry: ACETAMINOPHEN
Patent ExpiryPatent/Exclusivity Expiry: APADAZ
Patent ExpiryPatent/Exclusivity Expiry: OFIRMEV

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Readout: aleniglipron — GPCR Phase 2 Readout | BioSniper